<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between January 1986 and July 1990, 17 patients with acquired <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> were treated with ALG or ATG combined with high doses of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The mean age was 24.3 years (from 4 to 51 years) </plain></SENT>
<SENT sid="2" pm="."><plain>There were 9 cases with idiopathic etiology of acquired <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>; in 7 cases <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was developed during or after HBsAg <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In one case <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was developed during <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">tuberculous</z:e> <z:e sem="disease" ids="C0021313" disease_type="Disease or Syndrome" abbrv="">kidney infection</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The remission of the disease was achieved in 11 of 17 cases (complete remission in 9-53%, and partial in 2-12% patients) </plain></SENT>
<SENT sid="5" pm="."><plain>Six (35%) patients did not respond to the treatment with ALG </plain></SENT>
<SENT sid="6" pm="."><plain>One patient died of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and hemorrhagic complications, two weeks after the therapy, without responding to the treatment with ALG </plain></SENT>
<SENT sid="7" pm="."><plain>The four year survival rate without recidives was 65% (11/17) </plain></SENT>
<SENT sid="8" pm="."><plain>Four (23.5%) patients developed clonal diseases: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> in 2; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in 1 and AL in 1 patient, 24, 38, 9 and 6 months after the therapy with ALG, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The age of the patients is a valuable prognostic parameter (<z:hpo ids='HP_0000001'>all</z:hpo> patients under 20 years of age entered the remission), which cannot be said for pretreatment levels of reticulocytes, neutrophils and platelets </plain></SENT>
<SENT sid="10" pm="."><plain>In none of the patients adverse effects of ALG were observed </plain></SENT>
<SENT sid="11" pm="."><plain>The treatment was conducted in isolated rooms with <z:mp ids='MP_0001924'>sterile</z:mp> air circulation </plain></SENT>
<SENT sid="12" pm="."><plain>ALG combined with high doses of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi>, for the majority of patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> represents a drug of choice and is an appropriate alternative therapy to alogenic bone marrow transplantation, especially for patients with no HLA identical bone marrow donor </plain></SENT>
</text></document>